文献速递传染病防控与疫情报告卫生政策与健康促进

阿片受体激动剂治疗维持轨迹与非致命性过量风险的关联

Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting.
PubMed 文献 · Am J Prev Med · 2021-01-01

研究基于加拿大温哥华两个社区招募的前瞻性队列,对438名启动阿片受体激动剂治疗(OAT)的阿片使用障碍者进行潜在类别增长分析,识别出4种维持轨迹。调整分析显示,持续低维持(AOR=1.73,95%CI=1.10–2.71)和下降维持(AOR=1.87,95%CI=1.18–2.95)轨迹与非致命性过量风险升高相关。

要点

  • OAT持续低维持和下降维持轨迹与非致命性过量风险增加相关。
  • 持续高维持轨迹占35.6%,可作为理想治疗目标参照。
  • 减少持续参与OAT的障碍对应对过量流行至关重要。

核心结论

  • OAT维持轨迹不佳与非致命性过量可能性增加相关。
  • 减少持续参与OAT的障碍对应对北美过量流行至关重要。

研究设计与样本

  • 数据来自加拿大温哥华两个社区招募的药物使用者前瞻性队列。
  • 采用潜在类别增长分析识别438名OAT启动者的维持轨迹,并用广义估计方程评估与非致命性过量的关联。

主要发现

  • 2005–2018年间,438名OAT启动者中识别出4种维持轨迹:持续高(35.6%)、上升(26.0%)、持续低(23.3%)、下降(15.1%)。
  • 研究期间共发生371例非致命性过量事件,179名(40.1%)参与者报告至少1次。
  • 调整分析中,持续低维持轨迹(AOR=1.73,95%CI=1.10–2.71)和下降维持轨迹(AOR=1.87,95%CI=1.18–2.95)相较于持续高维持轨迹与非致命性过量风险升高正相关。

临床怎么用

  • 应将OAT维持轨迹纳入过量风险评估,对持续低维持或下降维持者加强监测与干预。
  • 针对减少持续参与OAT的障碍采取措施,以降低非致命性过量风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Retention in opioid agonist therapy consistently has been linked with improved outcomes among people with opioid use disorder. However, less is known about the links between patterns of engagement in opioid agonist therapy over the long term and overdose risk. This study assesses the association of opioid agonist therapy retention trajectories with nonfatal overdose. METHODS: Data were drawn from 2 community-recruited prospective cohorts of people who use drugs in Vancouver, Canada. Latent class growth analysis was used to identify trajectories of opioid agonist therapy retention among people with opioid use disorder initiating therapy, and generalized estimating equations assessed the association of these trajectories with nonfatal overdose events after opioid agonist therapy initiation. RESULTS: Between 2005 and 2018, among 438 opioid agonist therapy initiators, 4 retention trajectories were identified: consistently high (35.6%), increasing (26.0%), consistently low (23.3%), and decreasing (15.1%) opioid agonist therapy engagement. During the study period, there were 371 nonfatal overdose events, with 179 (40.1%) participants reporting ≥1. In adjusted analysis, the consistently low (AOR=1.73, 95% CI=1.10, 2.71) and decreasing (AOR=1.87, 95% CI=1.18, 2.95) retention trajectories were positively associated with increased odds of nonfatal overdose compared with the consistently high opioid agonist therapy retention class. CONCLUSIONS: Suboptimal trajectories of opioid agonist therapy retention were associated with an increased likelihood of nonfatal overdose. These findings suggest that reducing the barriers to sustained engagement in opioid agonist therapy will be critical to address North America's overdose epidemic.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Socías ME, Dong H, Wood E, et al. Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting. Am J Prev Med. 2021. PMID: 33341181. doi:10.1016/j.amepre.2020.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。